Xenetic Biosciences, Inc. (NASDAQ:XBIO) has filed a preliminary prospectus for a public offering of 1,555,555 common shares and warrants to purchase same number of common shares, at a combined price of $11.25 per share and warrant.
The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the XBIO is 58.20%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the XBIO is 10.80%.
Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that XBIO. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public.
Institutional ownership is the amount of a Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others.
a Healthcare sector firm, Xenetic Biosciences, Inc. (NASDAQ:XBIO) stock fell -2.76% on Monday and when day-trade ended the stock finally concluded at $10.94 and number of shares that changed hands during the day are 102325. The number of shares XBIO stock currently held by all its shareholders are 0.64 and floated shares, the number of shares are available for trading in an open market on last trading day are 0.37. The average volume of shares for 3 months is 31.82 and XBIO stock value has moved between $6.11 – 78.14 in last one year.
The Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s latest earnings date is 8/9/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The stock has gained -44.41% in 2019 to date.
U.S. traded shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s monthly stock performance is 34.07%, the quarterly performance is -50.99%, the half year performance is calculated as -44.75%. The yearly performance of XBIO is -80.44%.
The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Xenetic Biosciences, Inc. (NASDAQ:XBIO) weekly volatility is measured as 41.31% and monthly volatility measured as 22.79%.
Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. XBIO return on assets is -67.10%, the return on equity (ROE) of the Xenetic Biosciences, Inc. (NASDAQ:XBIO) is -93.90%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions.
The price to book ratio is 0.77, price to cash per share ration is 3.50.
Analysts mean target price for Xenetic Biosciences, Inc. (NASDAQ:XBIO) is $10.00. The current share price indicates that stock is -85.73% away from its one year high and is moving 78.76% ahead of its 52-week low. XBIO’s distance from 20 day simple moving average is 39.68% and distance from 50-Day simple moving average is -4.32%.